Immune signaling in IBD triggers tumor-promoting neutrophils which is linked to an increased risk of colorectal cancer.

Trojan horse” approach may enable ‘antigen-independent’ therapy with potential to treat cancers not traditionally amenable to immunotherapy.

When the team knocked out the P2Y2 receptor in drug-resistant cancer cells, it led to an almost complete loss of the mutant EGFR protein.

MYC‑driven tumors silence innate immune alarms by clearing R‑loop–derived signals, exposing a new therapeutic angle for targeting MYC without broad inhibition.

Reducing manual touchpoints is an important part of supporting more consistent and scalable manufacturing processes.